Drug Trial Radar · NCT00265291
Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group
Last checked: Nov 20, 2026Latest source record: Oct 10, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
700
Actual
Start
Nov 1999
Primary completion
May 2006
Study completion Oct 2008
Sponsor
- Lead sponsor
- National Institute of General Medical Sciences (NIGMS)NIH
- Sponsor type
- NIH
- First posted
- Dec 14, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Our goal is to study pharmacogenetics in Mexican-Americans, using depression treatments as a proof of the concept that pharmacogenetic approaches can be used to optimize treatment strategies for common and complex disorders in this population.
Conditions
- Major Depressive Disorder
- Major Depression
- Unipolar Depression
Interventions
fluoxetine or desipramineDrug
fluoxetine 5-40 mg/day desipramine 50-150 mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Hamilton Depression Rating Scale (HAM-D) on a weekly basisTime frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center for Pharmacogenomics, University of Miami
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.